Minocycline Hydrochloride

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety , and vonoprazan use post endoscopic submucosal dissection (ESD) Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA ® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois. Phathom presented three posters at the meeting, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study that was recognized by DDW as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. Vonoprazan was also the subject of 28 additional independent, investigator-initiated abstracts across gastroesophageal reflux disease (GERD), Helicobacter pylori ( H. pylori ) eradication, long-term safety, and post endoscopic procedural care, reflecting the growing scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class in GI medicine. “The breadth of data presented at DDW 2026 reflects the significant scientific interest in vonoprazan across multiple acid-related conditions,” said Steve Basta, President and Chief Executive Officer of Phathom. “We are encouraged by the level of independent scientific engagement and the broad interest among researchers to evaluate vonoprazan in a range of conditions. The research highlighted at this year’s meeting adds to the growing scientific understanding of vonoprazan across multiple areas of GI medicine.” Key data presented at DDW 2026 include: Meta-analysis of data from randomized controlled trials evaluating healing outcomes in patients with severe (LA Grade C and D) erosive esophagitis (Erosive GERD) treated with vonoprazan compared to the proton pump inhibitor (PPI) lansoprazole Analyses from the Phase 3 pHalcon-NERD-301 study evaluating both heartburn and regurgitation symptoms in patients with Non-Erosive GERD (NERD) treated with vonoprazan versus placebo, as measured by the validated PAGI-SYM patient-reported outcome instrument Real-world data evaluating vonoprazan in patients with PPI-refractory GERD following laparoscopic sleeve gastrectomy Multiple independent meta-analyses evaluating H. pylori eradication rates with vonoprazan-based regimens, including a network meta-analysis of 77 randomized controlled trials comparing treatment strategies Real-world propensity-matched cohort analyses evaluating safety outcomes associated with vonoprazan and traditional PPIs, including rates of vitamin B12 deficiency, hypomagnesemia, and Clostridioides difficile ( C. diff ) infection Two independent systematic reviews and meta-analyses evaluating delayed post-procedural bleeding following endoscopic submucosal dissection (ESD) in patients treated with vonoprazan compared to PPIs Post hoc analyses from the multicenter, prospective, real-world observational study evaluating vonoprazan in Chinese patients with reflux esophagitis across patient subpopulations including elderly patients and those with comorbid anxiety or depression Vonoprazan Abstracts Presented at DDW 2026: 28 independent abstracts reflect investigator-initiated research conducted by academic and clinical scientists across the United States, Europe, Asia, and South America: Independent Research on Vonoprazan: GERD Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Patients with Grade C and D Erosive Esophagitis: A Meta-Analysis ( He E et al. ; Tu1173) Use Morning or/and Evening Dosing of Vonoprazan for Gastroesophageal Reflux Disease: An Interim Analysis for a Randomized Crossover Trial ( Wang D et al. ; Tu1163) Real-World Prescription Patterns of Potassium-Competitive Acid Blockers (PCABs) in Erosive Esophagitis: A New Era in Acid Suppression ( Chalhoub M et al. ; Tu1167) Effectiveness and Safety of Vonoprazan in Elderly Chinese Patients with Gastroesophageal Reflux Disease: A Post Hoc Analysis of the VIEW Study ( Liang K et al. ; Tu1165) Effectiveness of Vonoprazan on Symptom Relief in Gastroesophageal Reflux Disease Patients with Anxiety or Depression: A Post Hoc Analysis of the VIEW Study ( Liang K et al. ; Tu1168) Vonoprazan Improves GERD Symptoms and Heals Erosive Esophagitis in Patients with Gastric Sleeve Refractory to High Dose PPI ( Cricco-Lizza E et al. ; Presentation 972) Safety Real World Evaluation of Adverse Events Associated with Vonoprazan Compared with Traditional Proton Pump Inhibitors ( Al Momani Z et al. ; Su1277) Long Term Safety of Vonoprazan Compared with Proton Pump Inhibitors: A Large Multi-Center Real World Propensity Matched Cohort ( Alsafi W et al. ; Tu1221) The Risk of Clostridioides Difficile Infection with Vonoprazan Compared to Proton Pump Inhibitors: A Large Multi-Center Cohort Study ( Cohen E et al. ; Sa1333) Potassium-Competitive Acid Blockers and Risk of Small Intestinal Bacterial Overgrowth and Nutrient Deficiencies: A Global Real-World Study ( Luo A et al. ; Su1273) Vonoprazan Does Not Increase the Incidence of Benign Gastric Polyps Compared with Proton Pump Inhibitors ( Simadibrata D et al. ; 1123) PCABs Are Associated with Low Rates of Short-Term Adverse Events: A Global Cohort Study Comparing PCABs Versus PPIs ( Lee ME et al. ; Poster 963) H. pylori Eradication First-Line Empirical Eradication Therapy for H. pylori Infection: Experience from 1,500 Cases of the Brazilian H. pylori Registry ( Friche Passos M et al. ; Tu1224) Efficacy of Potassium-Competitive Acid Blocker (PCAB)-Based Therapies for H. pylori Infection: A Network Meta-Analysis of 77 Randomized Controlled Trials ( Song Z et al. ; Tu1223) Comparative Efficacy and Safety of Vonoprazan-Based Dual Therapy Versus Bismuth-Based Quadruple Therapy for H. pylori: A GRADE-Assessed Meta-Analysis with Trial Sequential Analysis ( Navabi S et al. ; Tu1222) Vonoprazan Based Therapy Outperforms Proton Pump Inhibitor Regimens for H. pylori Eradication: A Review of Six Meta-Analyses ( Chakinala R et al. ; Tu1219) Simplicity Without Compromise: An Updated Meta-Analysis of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapy for H. pylori Eradication ( Zahid M et al. ; Tu1205) Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapy for H. pylori: A Systematic Review and Meta-Analysis ( Haider A et al. ; Tu1204) Comparative Efficacy and Safety of Vonoprazan Triple Therapy Versus PPI and Bismuth Based Quadruple Therapy for H. pylori: A Systematic Review and Meta-Analysis ( Gundapaneni S et al. ; Tu1200) Ten Versus Fourteen Days of Vonoprazan-Based Therapy for H. pylori: A Systematic Review and Meta-Analysis ( Alsaleh T et al. ; Tu1211) Efficacy and Safety of 14-Day Bismuth-Containing Quadruple Therapy with Low-Dose Vonoprazan Versus Esomeprazole for H. pylori Eradication: A Real-World Multicenter Study ( Lin H et al. ; Tu1213) Efficacy and Safety of Vonoprazan Dual Versus Quadruple Therapy for H. pylori Second-Line Treatment: A Real-World Study ( Li P et al. ; Tu1209) P-CAB/Minocycline/Furazolidone/Bismuth Quadruple Regimen for Refractory H. pylori Infection: A Multicenter Study ( Li P et al. ; Tu1199) Vonoprazan Plus High-Dose Amoxicillin Dual Therapy Versus PPI-Based Low-Dose Amoxicillin Quadruple Therapy for H. pylori: A Systematic Review and Meta-Analysis ( Patel R et al. ; Tu1220) Vonoprazan-Tetracycline Dual Therapy as a Simplified Rescue Regimen for Helicobacter Pylori: A Randomized Non-Inferiority Trial ( Li J et al. ; Poster 437) Transforming Amoxicillin Therapy into a Grade-A Eradication Regimen with Vonoprazan and Bismuth: A Multicenter Randomized Trial ( Hsu P et al. ; Poster 861) Vonoprazan Use Post Endoscopic Submucosal Dissection Potassium-Competitive Acid Blockade After ESD: Does Vonoprazan Outperform PPIs? A Systematic Review and Meta-Analysis ( Ginnaram S et al. ; Su1226) Vonoprazan Versus Proton Pump Inhibitors for Prevention of Delayed Bleeding After Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis ( Singh S et al. ; Sa2164) Phathom-Sponsored Research on Vonoprazan: Assessment of Heartburn and Regurgitation in Symptomatic Non-Erosive Gastroesophageal Reflux Disease Patients on Vonoprazan: Exploratory Analysis of PAGI-SYM [Poster of Distinction] ( Fass R et al. ; Tu1159) Patient Reported Outcomes, Patient Experience, and Treatment Satisfaction with Prescription Treatments for Gastroesophageal Reflux Disease: A Real-World Survey of U.S. Adults ( Shaheen N et al. ; Tu1164) A Phase 1, Open-Label Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg QD or BID ( Chang YM et al. ; Su1272) About VOQUEZNA ® (vonoprazan) VOQUEZNA ® (vonoprazan) tablets contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the U.S. for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, the relief of heartburn associated with Erosive GERD, the relief of heartburn associated with Non-Erosive GERD, and for the treatment of H. pylori infection in combination with either amoxicillin or amoxicillin and clarithromycin. Any other uses of vonoprazan as described in the research presented at DDW are investigational in the U.S. and Phathom makes no representations concerning the safety or efficacy of such investigational uses. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and numerous other countries in Asia and Latin America. INDICATIONS AND USAGE VOQUEZNA ® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults: for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD. to maintain healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD. for the relief of heartburn associated with Non-Erosive GERD. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection. in combination with amoxicillin for the treatment of H. pylori infection. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products. For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with VOQUEZNA, refer to the Contraindications section of the corresponding prescribing information. WARNINGS AND PRECAUTIONS Presence of Gastric Malignancy: In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy. Acute Tubulointerstitial Nephritis: Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN. Clostridioides difficile -Associated Diarrhea: Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridioides difficile -associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. CDAD has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with VOQUEZNA, refer to Warnings and Precautions section of the corresponding prescribing information. Bone Fracture: Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer). Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines. Severe Cutaneous Adverse Reactions (SCAR): Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation. Vitamin B12 (Cobalamin) Deficiency: Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup. Hypomagnesemia and Mineral Metabolism: Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients. Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA. Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA. Interactions with Diagnostic Investigations for Neuroendocrine Tumors: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 4 weeks before assessing CgA levels and consider repeating the test if initial CgA levels are high. Fundic Gland Polyps: Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. ADVERSE REACTIONS: Healing of Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%). Maintenance of Healed Erosive GERD: The most common adverse reactions (≥3% of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%). Relief of Heartburn Associated with Non-Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include abdominal pain (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract infection (2%). Treatment of H. Pylori Infection (VOQUEZNA and Amoxicillin): The most common adverse reactions (≥2% in any treatment arm) include diarrhea (5%), abdominal pain (3%), vulvovaginal candidiasis (2%), nasopharyngitis (2%), dysgeusia (1%), headache (1%), and hypertension (1%). Treatment of H. Pylori Infection (VOQUEZNA, Amoxicillin and Clarithromycin): The most common adverse reactions (≥2% in any treatment arm) include dysgeusia (5%), diarrhea (4%), vulvovaginal candidiasis (3%), headache (3%), abdominal pain (2%), hypertension (2%), and nasopharyngitis (<1%). For more information on adverse reactions and laboratory changes with amoxicillin or clarithromycin, refer to Adverse Reactions section of the corresponding prescribing information. DRUG INTERACTIONS VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. For information about drug interactions, contraindications, and warnings and precautions of antibacterial agents (amoxicillin or clarithromycin) indicated in combination with VOQUEZNA, refer to their corresponding prescribing information. USE IN SPECIFIC POPULATIONS Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting Lactation: There are no data on the effects of vonoprazan on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VOQUEZNA and any potential adverse effects on the breastfed child from VOQUEZNA or from the underlying maternal condition. Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min). Use of VOQUEZNA is not recommended for the treatment of H. pylori infection in patients with severe renal impairment. Hepatic Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C). Use of VOQUEZNA is not recommended for the treatment of H. pylori infection in patients with moderate to severe hepatic impairment. You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888- 775-PHAT (7428) or FDA at 1-800-FDA-1088 or Please click here to see full Prescribing Information for VOQUEZNA. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at follow on LinkedIn and X. About DDW Digestive Disease Week ® (DDW) is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting. Forward-Looking Statements This press release contains forward-looking statements, including without limitation statements regarding: the significance, interpretation and potential implications of data presented at DDW 2026; the scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class; the potential efficacy, safety and tolerability pro VOQUEZNA® (vonoprazan); and the relevance and applicability of analyses, meta-analyses, real-world studies, post hoc analyses and investigator-initiated research discussed in this press release. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: the data, analyses and other information presented at DDW 2026 may not be predictive or indicative of future research findings, clinical outcomes or real-world results; exploratory analyses, post hoc analyses, meta-analyses, retrospective studies and investigator-initiated research are subject to inherent limitations and may be interpreted differently following additional review, analysis or peer review; additional data or analyses may alter the interpretation or significance of results discussed in this press release; regulatory review may differ from or not support the conclusions suggested by the data discussed in this press release or future data, analyses; and market acceptance for VOQUEZNA from healthcare professionals, patients and payors in the indications for which it is approved may be lower than we anticipate. For additional discussion of these and other risks, see the risk disclosure in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc. 05/26 US-VPZ-26-0175

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2026. Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2026 is off to a strong start, as we delivered solid revenue growth and cash generation in the first quarter of the year. Prescription demand and payer coverage for Emrosi ® continue to increase, with the product’s differentiated clinical pro traction as we establish Emrosi ® as the best-in-class oral treatment for patients suffering from rosacea. Increasing refill rates and a growing number of Emrosi ® prescribers are also building momentum behind the brand. Our net product sales growth in the quarter coupled with disciplined investment in our dermatology-focused commercial infrastructure resulted in improved operating leverage, and we expect this trend to continue going forward. With over $27 million in cash and Emrosi ® entering its second year on the market, we remain well-positioned to continue to execute on our strategy and deliver strong financial progress throughout the year.” Financial Results: Total revenues were $16.0 million for the first quarter of 2026, reflecting a 21% increase from $13.1 million for the first quarter of 2025. The increase was driven by continued growth in Emrosi ® , which generated revenues of $6.3 million for the quarter ended March 31, 2026, compared to $2.1 million for the quarter ended March 31, 2025. The Company’s gross margin ( 1) decreased to 61.0% for the first quarter of 2026, from 63.5% in the first quarter of 2025. The decrease resulted primarily from a $1.3 million non-recurring non-cash charge against cost of goods during the first quarter of 2026 associated with a write down of active pharmaceutical ingredient (API) inventory related to the 2021 Qbrexza ® asset acquisition. Selling, general and administrative expenses decreased by $0.5 million to $10.1 million for the three-month period ended March 31, 2026, from $10.6 million for the three-month period ended March 31, 2025. The decrease is primarily due to lower Emrosi ® launch costs compared to the prior year quarter. Net loss for the Company narrowed to $2.2 million, or $(0.08) per share basic and diluted, for the first quarter of 2026, compared to a net loss of $4.1 million, or $(0.18) per share basic and diluted, for the first quarter of 2025. The Company’s non-GAAP results in the table below reflect positive Adjusted EBITDA of $0.6 million, or $0.02 per share basic and diluted for the first quarter of 2026. This compares to negative Adjusted EBITDA of $(0.9) million, or $(0.04) loss per share basic diluted for the first quarter of 2025. Adjusted EBITDA, Adjusted EBITDA per share basic and Adjusted EBITDA per share diluted are non-GAAP financial measures, each of which are reconciled to the most directly comparable financial measures calculated in accordance with GAAP below. At March 31, 2026, the Company had $27.2 million in cash and cash equivalents as compared to $24.1 million in cash and cash equivalents at December 31, 2025. Recent Corporate Highlights: Emrosi ® prescriptions totaled 29,968 for the first quarter of 2026 versus 27,023 in the fourth quarter of 2025. On April 21, 2026, the Company announced that it secured a contract with the third largest Group Purchasing Organization (GPO) in the United States for Emrosi ® . With this contract in place, approximately 85% of all commercial lives in the nation have access to Emrosi ® . Expanded payer access is anticipated to facilitate further growth in Emrosi ® prescription demand. Conference Call and Webcast Information Journey Medical management will conduct a conference call and audio webcast on May 13, 2026, at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Journey Medical conference call. Participants can register for the conference call here: . Please note that registered participants will receive their dial-in number upon registration. A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, , and will remain available for replay for approximately 30 days after the meeting. (1) We define gross margin as total revenue less cost of goods sold divided by total revenue. About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit . Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition because their period of exclusivity has ended or they are without patent protection, subjecting them to the potential introduction of new competitor products and/or an increase in market share of existing competitor products, either of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance on third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of Emrosi ® and the successful development, regulatory approval and commercialization of any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt expressed about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contact: Jaclyn Jaffe (781) 652-4500 ir@jmcderm.com Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com JOURNEY MEDICAL CORPORATION Unaudited Condensed Consolidated Balance Sheets ($ in thousands except for share and per share amounts) March 31, December 31, 2026 2025 ASSETS Current assets Cash and cash equivalents $ 27,219 $ 24,090 Accounts receivable, net of reserves 24,992 29,783 Inventory 9,292 9,624 Prepaid expenses and other current assets 3,464 3,376 Total current assets 64,967 66,873 Intangible assets, net 26,479 27,605 Operating lease right-of-use asset, net 88 111 Total assets $ 91,534 $ 94,589 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 8,202 $ 8,851 Due to related party 472 455 Accrued expenses 26,102 27,567 Accrued interest 390 398 Income taxes payable 70 70 Term loan, short-term 2,500 - Operating lease liability, short-term 94 101 Total current liabilities 37,830 37,442 Term loan, long-term, net of discount 22,873 25,277 Operating lease liability, long-term - 18 Total liabilities 60,703 62,737 Stockholders' equity Common stock, $.0001 par value, 50,000,000 shares authorized, 21,333,946 and 21,144,655 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 2 2 Common stock - Class A, $.0001 par value, 50,000,000 shares authorized, 6,000,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025 1 1 Additional paid-in capital 131,516 130,307 Accumulated deficit (100,688 ) (98,458 ) Total stockholders' equity 30,831 31,852 Total liabilities and stockholders' equity $ 91,534 $ 94,589 JOURNEY MEDICAL CORPORATION Unaudited Condensed Consolidated Statements of Operations ($ in thousands except for share and per share amounts) ​ Three-Month Periods Ended March 31, 2026 2025 Revenue: ​ ​ ​ ​ ​ Product revenue, net $ 15,921 ​ $ 13,139 Other revenue 40 - Total revenue 15,961 13,139 Operating expenses ​ ​ ​ ​ ​ Cost of goods sold – (excluding amortization of acquired intangible assets) ​ 6,218 4,790 Amortization of acquired intangible assets 1,126 1,065 Research and development ​ - 39 Selling, general and administrative ​ 10,109 10,569 Total operating expenses ​ 17,453 ​ ​ 16,463 Loss from operations ​ (1,492 ) ​ ​ (3,324 ) Other expense (income) Interest income (157 ) (149 ) Interest expense ​ 892 891 Foreign exchange transaction losses 3 7 Total other expense ​ 738 ​ ​ 749 Loss before income taxes ​ (2,230 ) ​ ​ (4,073 ) Income tax expense - - Net loss $ (2,230 ) ​ $ (4,073 ) Net loss per common share: Basic and diluted $ (0.08 ) ​ $ (0.18 ) Weighted average number of common shares: Basic and diluted 27,305,028 22,611,040 Use of Non-GAAP Measures: In addition to the GAAP financial measures as presented in our Form 10-Q that will be filed with the Securities and Exchange Commission (“SEC”), the Company has, in this press release, included certain non-GAAP measurements, including EBITDA, Adjusted EBITDA, Adjusted EBITDA per share basic and Adjusted EBITDA per share diluted. We define EBITDA as net income (loss) excluding interest, taxes and depreciation and amortization and we define Adjusted EBITDA as net income (loss) excluding interest, taxes and depreciation, less certain other non-cash and/or infrequent items not considered to be normal, recurring operating expenses, including, share-based compensation expense, amortization and impairments of acquired intangible assets, inventory step-ups from the purchases of intangibles assets and products, severance, and foreign exchange transaction losses. In particular, we exclude the following matters for the reasons more fully described below: Share-Based Compensation Expense : We exclude share-based compensation from our adjusted financial results because share-based compensation expense, which is non-cash, although a recurring expense, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Amortization and impairments of Acquired Intangible assets : We exclude the impact of certain amounts recorded in connection with the acquisitions of intangible assets that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. These amounts may include non-cash items such as the amortization impairments of acquired intangible assets and amortization of step-ups of acquisition accounting adjustments to inventories. Beginning in the first quarter of 2026, we no longer exclude short-term research and development expenses (including any one-time license and milestone payments) from our Non-GAAP Adjusted EBITDA results. Prior period Non-GAAP Adjusted EBITDA results have been revised to reflect this change. Adjusted EBITDA per share basic and Adjusted EBITDA per share diluted are determined by dividing the resulting Adjusted EBITDA by the number of shares outstanding on an actual and fully diluted basis. Management believes the use of these non-GAAP measures provides meaningful supplemental information regarding the Company’s performance because (i) they allow for greater transparency with respect to key measures used by management in its financial and operational decision-making, (ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance and (iii) they are used by institutional investors and the analyst community to help analyze the Company's results. However, Adjusted EBITDA, Adjusted EBITDA per share basic, Adjusted EBITDA per share diluted and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the manner in which they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors. The table below provides a reconciliation from GAAP to non-GAAP measures: JOURNEY MEDICAL CORPORATION (unaudited) Reconciliation of GAAP to Non-GAAP Adjusted EBITDA ($ in thousands except for share and per share amounts) Three-Month Periods Ended March 31, 2026 2025 GAAP Net Loss $ (2,230 ) $ (4,073 ) EBITDA: Interest 735 742 Taxes - - Amortization of acquired intangible assets 1,126 1,065 EBITDA (369 ) (2,266 ) Non-GAAP Adjusted EBITDA: Non-Cash Components: Share-based compensation 989 1,323 Non-Core and Infrequent Components: Foreign exchange transaction losses 3 7 Non-GAAP Adjusted EBITDA $ 623 $ (936 ) Net loss & Non-GAAP Adjusted EBITDA per common share: Basic GAAP Net Loss $ (0.08 ) $ (0.18 ) Non-GAAP Adjusted EBITDA $ 0.02 $ (0.04 ) Diluted GAAP Net Loss $ (0.08 ) $ (0.18 ) Non-GAAP Adjusted EBITDA $ 0.02 $ (0.04 ) Weighted average number of common shares: GAAP - Basic & Diluted 27,305,028 22,611,040 Non-GAAP - Basic 27,305,028 22,611,040 Non-GAAP - Diluted 29,701,725 22,611,040